Patients with gastric cancer are frequently malnourished with 30% to 38% of them losing more than 10% of their weight in preceding six months. Sarcopenia represents a decrease in the skeletal muscle mass and function and is usually associated with the aging process. The prevalence of sarcopenia in patients with gastric cancer is reported to be as high as 57.7%. Although many studies support the negative impact of sarcopenia in patients with gastric cancer, contradictory results are also present in the literature. The objective of this study is to investigate if sarcopenia is correlated with increased morbidity and mortality, in patients with gastric adenocarcinoma. We studied retrospectively all patients having radical resection for gastric adenocarcinoma managed in the Emergency Hospital of Bucharest between December 2014 and May 2016. ImageJ software was used to measure the patients' body composition. We identified the L3 landmark and extracted that corresponding single cross-sectional image contained within a CT study. We reviewed 89 patients who had gastrectomy for cancer, but 11 Computed Tomography images were not available for analysis. Therefore, the study group consisted of 78 patients of which 50 were (64.1%) males and 28 (35.9%) females. The average age of patients diagnosed with gastric cancer was 67.7 years (range 22 to 92 years). The primary tumor location was the middle third of the stomach in 45 patients (57.7%), and the second in the lower third of the stomach in 29 patients (37.2%). There were 72 (92.3%) patients who were living on discharge, with mortality in 6 (7.7%) patients. 72.22% of patients are sarcopenic, and 27.78% were non-sarcopenic. The average sarcopenia value for both males and females is 43.77. The greatest number of patients had a skeletal muscle index between 40.00 and 45.00. The second greatest is between 35.00 and 40.00. The muscular skeletal index correlated with the age of the patients. The overall complications rate and the surgical site infection rate correlated with the sarcopenia. Sarcopenia is highly prevalent in patients having surgery for gastric cancer in Romania and correlates with increased postoperative morbidity. Especially with the increased trend for neoadjuvant therapy, the multidisciplinary team should evaluate and address sarcopenia through the perioperative period.

Download full-text PDF

Source
http://dx.doi.org/10.21614/chirurgia.113.5.678DOI Listing

Publication Analysis

Top Keywords

gastric cancer
20
patients
17
patients gastric
16
sarcopenia
9
postoperative morbidity
8
morbidity mortality
8
mortality patients
8
patients radical
8
gastrectomy cancer
8
skeletal muscle
8

Similar Publications

Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.

Sci Rep

December 2024

Department of Gastroenterology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang city, Jiangxi province, China.

P2X7 receptor (P2X7R) plays a role in regulating tumor progression, but it is unclear whether P2X7R affects the pathological characteristics of patients with gastric cancer and the activity of gastric cancer cells. Therefore, this study preliminarily investigated the relationship between P2X7R and clinicopathological features of patients with gastric cancer, and further explored the effect of P2X7R on the proliferation, migration and invasion of gastric cancer cells through functional experiments. The results showed that P2X7R was highly expressed in gastric cancer tissues and gastric cancer cells.

View Article and Find Full Text PDF

Objective: The RATIONALE-305 trial demonstrated that tislelizumab in combination with chemotherapy regimens was more beneficial than chemotherapy regimens alone in the treatment of patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC). This study aimed to evaluate the cost-effectiveness of tislelizumab combination chemotherapy in the treatment of advanced GC/GEJC from the perspective of the Chinese health service system.

Methods: A three-state partition survival model was constructed to evaluate the economics of tislelizumab combined with chemotherapy as the first-line treatment of advanced GC/GEJC.

View Article and Find Full Text PDF

Background: Triple-negative breast cancer (TNBC) is highly invasive and metastatic to the lymph nodes. Therefore, it is an urgent priority to distinguish novel biomarkers and molecular mechanisms of lymph node metastasis as the first step to the disease investigation. Long non-coding RNAs (lncRNAs) have widely been explored in cancer tumorigenesis, progression, and invasion.

View Article and Find Full Text PDF

Aldo-keto reductase family 1 member B10 (AKR1B10) is a member of the AKR1B subfamily. It is mainly found in cytoplasm, and it is typically expressed in the stomach and intestines. Given that its expression is low or absent in other tissues, AKR1B10 is a potential diagnostic and therapeutic biomarker for various digestive system diseases.

View Article and Find Full Text PDF

Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.

Front Immunol

December 2024

Department of Otolaryngology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.

Background: B-cell receptor-associated protein 31 (BCAP31) is a widely expressed transmembrane protein primarily located in the endoplasmic reticulum (ER), including the ER-mitochondria associated membranes. Emerging evidence suggests that BCAP31 may play a role in cancer development and progression, although its specific effects across different cancer types remain incompletely understood.

Methods: The raw data on BCAP31 expression in tumor and adjacent non-tumor (paracancerous) samples were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) and UCSC databases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!